

Appendix 1 (as supplied by the authors): Baseline demographics & outcomes for the metro Vancouver case series compared to other previous reports.

	Metro Vancouver, Canada	Northern California¹, USA	New York City², USA	Lombardy³, Italy	Seattle⁴, USA	Wuhan⁵, China
	n=117	n =113	n= 1281	n =1591	n =24	n= 52
Demographics						
Age, median (IQR)	69 (60-75)	63 (53-73)	NR	63 (56-70)	64 (18)	59.7 (13.3)
Female, n (%)	38 (32.5%)	39 (35%)	NR	287 (18%)	9 (38%)	17 (33%)
APACHE ^b II Score, median (IQR)	18 (10-28)	NR	NR	NR	NR	17 (14-19)
SOFA ^c Score at Admission, median (IQR)	6 (2-11)	NR	NR	NR	NR	4 (3-4) for survivors 6 (4-8) for non-survivors
PaO ₂ : FiO ₂ , median (IQR)	180 (148-216)	NR	NR	160 (114-220)	142 (94-177)	100 (67-127) for survivors 63 (52-74) for non-survivors ^a
Compliance (mL x cmH ₂ O ⁻¹), median (IQR)	35 (31-44)	NR	NR	NR	29 (25-36)	NR
Comorbidities, n (%)				*comorbidity data reported for 1043 of 1591		
Hypertension	54 (46.2%)	58 (51%)	NR	509 (49%)	NR	NR
Dyslipidemia	43 (36.8%)	NR	NR	188 (18%)	NR	NR
Diabetes Mellitus	36 (30.8%)	45 (40%)	NR	180 (17%)	14 (58%)	9 (17%)
None	31 (26.5%)	NR	NR	334 (32%)	NR	NR
Cardiovascular Disease	20 (17.1%)	NR	NR	223 (21%) ^b	NR	5 (10%)
Current or former tobacco smoker	16 (13.7%)	NR	NR	NR	5 (22%)	2 (4%)
Chronic Kidney Disease	15 (12.8%)	12 (11%)	NR	36 (3%)	5 (21%)	NR
Asthma	14 (12.0%)	8 (7%)	NR	NR	3 (14%)	NR
Chronic Obstructive Pulmonary Disease	8 (6.8%)		NR	42 (4%)	1 (4%)	NR
Active Malignancy	7 (6.0%)	6 (5%)	NR	81 (8%)	0 (0%)	2 (4%)
Congestive Heart Failure	4 (3.4%)	4 (4%)	NR	223 (21%) ^b	NR	NR
Hemorrhagic or ischemic stroke	4 (3.4%)	NR	NR	NR	2 (8%)	7 (13%)
Chronic liver disease	2 (1.7%)	7 (6%)	NR	28 (3%)	NR	NR
On admission to ICU, median (IQR)						
White cell count (x10 ⁹ /L)	8.1 (5.9-10.8)	7.3 (5.4-9.2)	NR	NR	8.43 (5.63-12.5)	
Lymphocytes (x10 ⁶ /L)	0.8 (0.5-1)	0.9 (0.7-1.2)	NR	NR	0.72 (0.52-1.4)	0.67 (0.38)
Platelet Count ((x10 ⁹ /L)	215 (161-271.5)	NR	NR	NR	NR	181 (48)
Serum Creatinine (µmol/L)	86 (70-114)	80 (71-106)	NR	NR	NR	79 (30)

Appendix to: Mitra AR, Fergusson NA, Lloyd-Smith E, et al. Baseline characteristics and outcomes of patients with COVID-19 admitted to intensive care units in Vancouver, Canada: a case series. *CMAJ* 2020. doi: 10.1503/cmaj.200794. Copyright © 2020 The Author(s) or their employer(s).

To receive this resource in an accessible format, please contact us at cmajgroup@cmaj.ca.

First 3 days in ICU, median (IQR)						
Highest D-dimer (µg/L)	1560 (740-4000)	NR	NR	NR	NR	NR
Highest Ferritin (ng/mL)	1125 (637-2058)	NR	NR	NR	NR	NR
Peak Serum Creatinine (µmol/L)	101 (79-148)	NR	NR	NR	95 (70-175)	NR
Highest C-Reactive Protein (CRP) (mg/L)	148 (87-232)	NR	NR	NR	NR	NR
Highest Troponin I (ng/L)	15 (7-40)	NR	NR	NR	2/13 (15%) had > 60	NR
Highest Troponin T (ng/L)	0.02 (0.02-0.08)	NR	NR	NR	NR	NR
Outcomes, n (%)						
Died in ICU	18 (15%)	34 (30%)	291 (23%)	405 (26%)	12 (50%)	32 (62%)
Currently in ICU	12 (10%)	45 (40%)	908 (71%)	920 (58%)	3 (13%)	12 (23%)
Currently in Hospital	16 (14%)			256 (16%)	4 (17%)	8 (15%)
Discharged Home	71 (61%)	34 (30%)	82 (6%)		5 (21%)	
No. Requiring Mechanical Ventilation	74 (63%)	103 (91%)	1,151 (90%)	1150 of 1300 (88%) who had data available	18 (75%)	22 (42%)

Abbreviations: BMI, Body Mass Index; IQR, Interquartile Range; ICU, intensive care unit; APACHE, Acute Physiology And Chronic Health Evaluation; SOFA, Sequential Organ Failure Assessment.

^aStudy inclusion criteria were need for mechanical ventilation or requiring FiO₂ > 60%.

^bCardiovascular disease and congestive heart failure were combined.

References:

¹Myers LC, Parod SM, Escobar GJ, Liu VX. Characteristic of Hospitalized Adults With COVID-19 in an Integrated Health Care System in California. *JAMA* Published online April 24, 2020. doi: 10.1001/jama.2020.7202

²Safiya Richardson, MPH; Jamie S. Hirsch, MA, et al. Presenting Characteristics, Comorbidities, and Outcomes Among 5700 Patients Hospitalized With COVID-19 in the New York City Area. *JAMA* Published online April 22, 2020. doi:10.1001/jama.2020.6775

³Grasselli G, Zangrillo A, Zanella A, et al. Baseline Characteristics and Outcomes of 1591 Patients Infected With SARS-CoV-2 Admitted to ICUs of the Lombardy Region, Italy. *JAMA*. Published online April 6, 2020. doi: 10.1001/jama.2020.5394.

⁴Bhatraju PK, Ghassemieh BJ, Nichols M, et al. Covid-19 in Critically Ill Patients in the Seattle Region - Case Series. *The New England journal of medicine*. Published online March 30, 2020. doi: 10.1056/NEJMoa2004500.

⁵Yang X, Yu Y, Xu J, et al. Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study. *The Lancet Respiratory Medicine*. Published online Feb 24, 2020. doi: 10.1016/S2213-2600(20)30079-5.